[go: up one dir, main page]

AR037255A1 - Composiciones farmaceuticas que contienen oxibutinina - Google Patents

Composiciones farmaceuticas que contienen oxibutinina

Info

Publication number
AR037255A1
AR037255A1 ARP020104230A ARP020104230A AR037255A1 AR 037255 A1 AR037255 A1 AR 037255A1 AR P020104230 A ARP020104230 A AR P020104230A AR P020104230 A ARP020104230 A AR P020104230A AR 037255 A1 AR037255 A1 AR 037255A1
Authority
AR
Argentina
Prior art keywords
drug
oxybutynin
dosage form
treatment
incontinence
Prior art date
Application number
ARP020104230A
Other languages
English (en)
Inventor
Juan Augusto Vergez
Marcelo Ricci
Original Assignee
Osmotica Argentina S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25538393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR037255(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osmotica Argentina S A filed Critical Osmotica Argentina S A
Publication of AR037255A1 publication Critical patent/AR037255A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee una composición farmacéutica y una forma de dosificación para el tratamiento de la incontinencia con oxibutinina y una segunda droga. La segunda droga puede ser cualquier droga para el tratamiento de la incontinencia. Dependiendo de la vía de administración, la forma de dosificación empleada, y la segunda droga que se utilice, la forma de dosificación puede incluir independientemente cantidades terapéuticas o subterapéuticas de oxibutinina y de la segunda droga. Realizaciones particulares incluyen una forma de dosificación que provee una liberación controlada de oxibutinina y de la segunda droga para mantener los niveles terapéuticos efectivos de oxibutinina y/o la segunda droga en un mamífero por un período de tiempo extendido. Se provee un dispositivo osmótico que comprende un núcleo bicapa. El dispositivo osmótico provee una liberación controlada dual de ambas drogas desde el núcleo. Se provee un método para el tratamiento de la incontinencia urinaria (por estrés o urgencia) con una composición farmacéutica y una forma de dosificación. Juntas, la oxibutinina y la segunda droga proveen un beneficio clínico general mejorado con relación a cualquiera de los agentes administrados solos y aproximadamente en la misma dosis.
ARP020104230A 2001-11-06 2002-11-06 Composiciones farmaceuticas que contienen oxibutinina AR037255A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/992,488 US20030185882A1 (en) 2001-11-06 2001-11-06 Pharmaceutical compositions containing oxybutynin

Publications (1)

Publication Number Publication Date
AR037255A1 true AR037255A1 (es) 2004-11-03

Family

ID=25538393

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020104230A AR037255A1 (es) 2001-11-06 2002-11-06 Composiciones farmaceuticas que contienen oxibutinina
ARP020104231A AR037256A1 (es) 2001-11-06 2002-11-06 Forma de dosificacion de liberacion controlada dual

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP020104231A AR037256A1 (es) 2001-11-06 2002-11-06 Forma de dosificacion de liberacion controlada dual

Country Status (7)

Country Link
US (2) US20030185882A1 (es)
EP (1) EP1461018A2 (es)
AR (2) AR037255A1 (es)
AU (2) AU2002363361A1 (es)
BR (1) BR0213948A (es)
UY (2) UY27533A1 (es)
WO (2) WO2003039436A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
KR20040098023A (ko) * 2002-03-26 2004-11-18 테바 파마슈티컬 인더스트리즈 리미티드 약물 미세입자
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
CA2494233A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050271691A1 (en) * 2003-02-21 2005-12-08 Cardio Combos Llc Prepackaged aqueous pharmaceutical formulations
JP2007501248A (ja) * 2003-08-06 2007-01-25 アルザ・コーポレーシヨン 増進した分散調合物による長時間にわたるトピラメートの均一送達
US7410978B2 (en) * 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
CA2536401C (en) 2003-11-04 2011-08-30 Shire Laboratories Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
WO2005065646A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms
EP1701708A2 (en) * 2003-12-29 2006-09-20 Alza Corporation Novel drug compositions and dosage forms of topiramate
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
WO2005079756A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
EP1629834A1 (en) * 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
ZA200707250B (en) 2005-01-27 2009-06-24 Alembic Ltd Extended release formulation of levetiracetam
AU2006261788B2 (en) 2005-06-27 2012-05-31 Valeant International Bermuda Modified-release formulations of a bupropion salt
CA2655596C (en) * 2006-06-27 2011-10-25 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
WO2009052353A2 (en) * 2007-10-17 2009-04-23 Dr. Reddy's Laboratories Ltd. Trospium pharmaceutical formulations
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
WO2011161504A1 (en) * 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
CN103156804A (zh) * 2011-12-13 2013-06-19 重庆医药工业研究院有限责任公司 一种奥昔布宁透皮凝胶及其制备方法
PL2851075T3 (pl) * 2012-05-14 2022-02-21 Shionogi & Co., Ltd. Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
CN103127023B (zh) * 2013-03-01 2014-08-27 河北天成药业股份有限公司 一种盐酸度洛西汀肠溶片及其制备方法
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
GB201708224D0 (en) * 2017-05-23 2017-07-05 Juniper Pharmaceuticals Uk Ltd Device
LT3746126T (lt) * 2018-01-30 2024-10-25 Apnimed, Inc. (Delaware) Miego apnėjos arba paprasto knarkimo gydymui skirti būdai ir kompozicijos
IL297877A (en) 2020-05-05 2023-01-01 Apnimed Inc Delaware Polymorphic forms of (r)-oxybutynin hydrochloride

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4309996A (en) * 1980-04-28 1982-01-12 Alza Corporation System with microporous releasing diffusor
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4552880A (en) * 1983-02-15 1985-11-12 Merrell Dow Pharmaceuticals Inc. Aroylimidazolones
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US4661583A (en) * 1985-06-24 1987-04-28 Ashland Oil, Inc. Reaction of bicyclic amide acetal with imide
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4867969A (en) * 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
US4662880A (en) * 1986-03-14 1987-05-05 Alza Corporation Pseudoephedrine, brompheniramine therapy
US4960416A (en) * 1986-04-30 1990-10-02 Alza Corporation Dosage form with improved delivery capability
US4863456A (en) * 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
EP0280737B1 (en) * 1986-08-20 1991-12-11 Teikoku Seiyaku Co., Ltd. Steroidal drug-containing preparation for external use
US4765957A (en) * 1986-12-29 1988-08-23 Carondelet Foundry Company Alloy resistant to seawater and other corrosive fluids
DE3716260C1 (de) * 1987-05-15 1988-07-28 Dyckerhoff & Widmann Ag Verfahren zur Justierung und Befestigung von Funktionsflaechen eines Fahrwegs einer elektromagnetischen Schnellbahn und Vorrichtung zur Durchfuehrung des Verfahrens
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4814181A (en) * 1987-09-03 1989-03-21 Alza Corporation Dosage form comprising fast agent delivery followed by slow agent delivery
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4904474A (en) 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006346A (en) 1988-04-28 1991-04-09 Alza Corporation Delivery system
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5006348A (en) * 1990-05-04 1991-04-09 Kraft General Foods, Inc. Method for manufacture of swiss cheese
DE59001019D1 (de) * 1990-06-13 1993-04-15 Manfred Oelsner Verfahren zur herstellung von pektin- und zuckerhaltigen zubereitungen, wie konfituere, marmelade od.gdl.
US5976571A (en) * 1991-01-31 1999-11-02 Port Systems, L.L.C. Method for making a multi-stage drug delivery system
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
JP2646170B2 (ja) 1992-06-24 1997-08-25 日本ヘキスト・マリオン・ルセル株式会社 徐放性塩酸オキシブチニン製剤
US5643155A (en) * 1993-11-02 1997-07-01 Kallassy; Charles Aquatic exercise device
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
AU7994694A (en) 1994-10-21 1996-05-15 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO1997016814A1 (en) 1995-11-03 1997-05-09 Sierra Semiconductor Corporation Yuv video backend filter
JP2665658B2 (ja) 1995-12-18 1997-10-22 住友特殊金属株式会社 希土類・鉄・コバルト・ボロン系正方晶化合物
ES2168610T3 (es) * 1996-03-12 2002-06-16 Alza Corp Composicion y forma galenica que contiene un antagonista opioide.
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
ES2141044B1 (es) * 1997-02-26 2001-02-01 Alza Corp Terapia con oxibutinina.
US5866184A (en) * 1997-03-12 1999-02-02 World Class Packaging Systems, Inc. Method of packaging a food product in a ventable package
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
CA2311755C (en) 1998-08-27 2010-03-23 Pharmacia & Upjohn Ab Therapeutic formulation for administering tolterodine with controlled release
AU1256399A (en) 1998-10-07 2000-04-26 Alza Corporation Controlled release dosage from comprising oxybutynin
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
CN1660435A (zh) * 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form

Also Published As

Publication number Publication date
UY27533A1 (es) 2003-05-30
US8241667B2 (en) 2012-08-14
WO2003039436A2 (es) 2003-05-15
WO2003039519A3 (es) 2004-03-25
US20030185882A1 (en) 2003-10-02
US20060177510A1 (en) 2006-08-10
UY27532A1 (es) 2003-05-30
AR037256A1 (es) 2004-11-03
WO2003039436A3 (es) 2004-02-26
AU2002363360A1 (en) 2003-05-19
BR0213948A (pt) 2004-08-31
AU2002363361A1 (en) 2003-05-19
WO2003039519A2 (es) 2003-05-15
EP1461018A2 (en) 2004-09-29

Similar Documents

Publication Publication Date Title
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
ES2314200T3 (es) Una combinacion de un antagonista de nmda e inhibidores de esterasa de acetilcolina par ael tratamiento de la enfermedad de alzheimer.
EP3478283A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
ES2714550T3 (es) Composiciones farmacéuticas y método para tratar la inflamación en ganado bovino y otros animales
Koerber et al. Coexistent psoriasis and bullous pemphigoid: a report of six cases
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
CR6458A (es) Composiciones de valdecoxib
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
US20070116730A1 (en) Pharmaceutical compositions
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
SV2002000969A (es) Composicion parenteral reconstituible
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AU2013208649A1 (en) Combination therapy for the treatment of cancer
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
PE20030830A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
ES2323646T3 (es) Uso de derivados de pirrol contra la ansiedad.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal